Atopic dermatitis, naevi count and skin cancer risk: A meta-analysis

Journal of Dermatological Science

Volumn 84, Issue 2, 2016, Pages 137-143

  Gandini, Sara ^a   Stanganelli, Ignazio ^b   Palli, Domenico ^c   De Giorgi, Vincenzo ^d   Masala, Giovanna ^c   Caini, Saverio ^c  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^c CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Atopic dermatitis; Cutaneous melanoma; Keratinocyte skin cancer; Meta analysis; Naevi count

Indexed keywords

ARTICLE; ATOPIC DERMATITIS; BASAL CELL CARCINOMA; CANCER RISK; CONSULTATION; CUTANEOUS MELANOMA; DISEASE ASSOCIATION; HIGH RISK POPULATION; HUMAN; MELANOMA; NEVUS; PHENOTYPE; PRIORITY JOURNAL; SELF EXAMINATION; SKIN CANCER; SKIN EXAMINATION; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; ADOLESCENT; ADULT; CARCINOMA, BASAL CELL; CHILD; CYTOLOGY; DERMATITIS, ATOPIC; FEMALE; KERATINOCYTE; MALE; META ANALYSIS; MIDDLE AGED; PRESCHOOL CHILD; RISK FACTOR; SKIN NEOPLASMS; YOUNG ADULT;

ADOLESCENT; ADULT; CARCINOMA, BASAL CELL; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; FEMALE; HUMANS; KERATINOCYTES; MALE; MELANOMA; MIDDLE AGED; NEVUS; PHENOTYPE; RISK FACTORS; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84994164628     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2016.07.009     Document Type: Article

References (62)

1. [1] Kiebert, G., Sorensen, S.V., Revicki, D., Fagan, S.C., Doyle, J.J., Cohen, J., Fivenson, D., Atopic dermatitis is associated with a decrement in health-related quality of life. Int. J. Dermatol. 41:March (3) (2002), 151–158.
2. [2] DaVeiga, S.P., Epidemiology of atopic dermatitis: a review. Allergy Asthma Proc. 33:May–June (3) (2012), 227–234.
3. [3] Nutten, S., Atopic dermatitis: global epidemiology and risk factors. Ann. Nutr. Metab. 66:Suppl. 1 (2015), 8–16.
4. [4] Blome, C., Radtke, M.A., Eissing, L., Augustin, M., Quality of life in patients with atopic dermatitis: disease burden, measurement, and treatment benefit. Am. J. Clin. Dermatol. 17:April (2) (2016), 163–169.
5. [5] Mancini, A.J., Kaulback, K., Chamlin, S.L., The socioeconomic impact of atopic dermatitis in the United States: a systematic review. Pediatr. Dermatol. 25:January–February (1) (2008), 1–6.
6. [6] Kim, C., Park, K.Y., Ahn, S., Kim, D.H., Li, K., Kim do, W., Kim, M.B., Jo, S.J., Yim, H.W., Seo, S.J., Economic impact of atopic dermatitis in korean patients. Ann Dermatol. 27:June (3) (2015), 298–305.
7. [7] Roekevisch, E., Spuls, P.I., Kuester, D., Limpens, J., Schmitt, J., Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J. Allergy Clin. Immunol. 133:February (2) (2014), 429–438.
8. [8] Dainichi, T., Hanakawa, S., Kabashima, K., Classification of inflammatory skin diseases: a proposal based on the disorders of the three-layered defense systems, barrier, innate immunity and acquired immunity. J. Dermatol. Sci. 76:November (2) (2014), 81–89.
9. [9] Flohr, C., Mann, J., New insights into the epidemiology of childhood atopic dermatitis. Allergy 69:January (1) (2014), 3–16.
10. [10] Boguniewicz, M., Leung, D.Y., Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol. Rev. 242:July (1) (2011), 233–246.
11. [11] Miyagaki, T., Sugaya, M., Recent advances in atopic dermatitis and psoriasis: genetic background, barrier function, and therapeutic targets. J. Dermatol. Sci. 78:May (2) (2015), 89–94.
12. [12] Tamagawa-Mineoka, R., Important roles of platelets as immune cells in the skin. J. Dermatol. Sci. 77:February (2) (2015), 93–101.
13. [13] Ehling, S., Roßbach, K., Dunston, S.M., Stark, H., Bäumer, W., Allergic inflammation is augmented via histamine H4 receptor activation: the role of natural killer cells in vitro and in vivo. J. Dermatol. Sci., 22(April), 2016 Epub ahead of print.
14. [14] Broberg, A., Augustsson, A., Atopic dermatitis and melanocytic naevi. Br. J. Dermatol. 142:February (2) (2000), 306–309.
15. [15] Rangwala, S., Tsai, K.Y., Roles of the immune system in skin cancer. Br. J. Dermatol. 165:November (5) (2011), 953–965.
16. [16] Arana, A., Wentworth, C.E., Fernández-Vidaurre, C., Schlienger, R.G., Conde, E., Arellano, F.M., Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K. Br. J. Dermatol. 163:November (5) (2010), 1036–1043.
17. [17] Jensen, A.O., Svaerke, C., Körmendiné Farkas, D., Olesen, A.B., Kragballe, K., Sørensen, H.T., Atopic dermatitis and risk of skin cancer: a Danish nationwide cohort study (1977–2006). Am. J. Clin. Dermatol. 13:February (1) (2012), 29–36.
18. [18] Bhattacharya, T., Nardone, B., Rademaker, A., Martini, M., Amin, A., Al-Mudaimeagh, H.M., Kiguradze, T., Schneider, D., West, D.P., Co-existence of psoriasis and melanoma in a large urban academic centre population: a cross-sectional retrospective study. J. Eur. Acad. Dermatol. Venereol. 30:January (1) (2016), 83–85.
19. [19] Ming, M.E., Levy, R., Hoffstad, O., Filip, J., Abrams, B.B., Fernández, C., Margolis, D.J., The lack of a relationship between atopic dermatitis and nonmelanoma skin cancers. J. Am. Acad. Dermatol. 50:March (3) (2004), 357–362.
20. [20] Stroup, D.F., Berlin, J.A., Morton, S.C., Olkin, I., Williamson, G.D., Rennie, D., Moher, D., Becker, B.J., Sipe, T.A., Thacker, S.B., Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283:April (15) (2000), 2008–2012.
21. [21] Haynes, R.B., Kastner, M., Wilczynski, N.L., Hedges Team, Developing optimal search strategies for detecting clinically sound and relevant causation studies in EMBASE. BMC Med. Inform. Decis. Mak., 5(March), 2005, 8.
22. [22] Shojania, K.G., Bero, L.A., Taking advantage of the explosion of systematic reviews: an efficient MEDLINE search strategy. Eff. Clin. Pract. 4:July–August (4) (2001), 157–162.
23. [23] Greenland, S., Quantitative methods in the review of epidemiologic literature. Epidemiol. Rev. 9 (1987), 1–30.
24. [24] van Houwelingen, H.C., Arends, L.R., Stijnen, T., Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat. Med. 21:February (4) (2002), 589–624.
25. [25] Higgins, J.P., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat. Med. 21:June (11) (2002), 1539–1558.
26. [26] Macaskill, P., Walter, S.D., Irwig, L., A comparison of methods to detect publication bias in meta-analysis. Stat. Med. 20:February (4) (2001), 641–654.
27. [27] Kallas, M., Rosdahl, I., Fredriksson, M., Synnerstad, I., Frequency and distribution pattern of melanocytic naevi in Estonian children and the influence of atopic dermatitis. J. Eur. Acad. Dermatol. Venereol. 20:February (2) (2006), 143–148.
28. [28] Uter, W.J., Pfahlberg, A.B., Gefeller, O., Nevus density and atopic eczema. Arch. Dermatol. 141:January (1) (2005), 101–102 author reply 102.
29. [29] Synnerstad, I., Nilsson, L., Fredrikson, F., Rosdahl, I., Fewer melanocytic nevi found in children with active atopic dermatitis than in children without dermatitis. Arch. Dermatol. 140 (2004), 1471–1475.
30. [30] Dellavalle, R.P., Hester, E.J., Stegner, D.L., Deas, A.M., Pacheco, T.R., Mokrohisky, S., Morelli, J.G., Crane, L.A., Is high mole count a marker of more than melanoma risk? Eczema diagnosis is associated with melanocytic nevi in children. Arch. Dermatol. 140:May (5) (2004), 577–580.
31. [31] Hagströmer, L., Ye, W., Nyrén, O., Emtestam, L., Incidence of cancer among patients with atopic dermatitis. Arch. Dermatol. 141:September (9) (2005), 1123–1127.
32. [32] Hwang, C.Y., Chen, Y.J., Lin, M.W., Chen, T.J., Chu, S.Y., Chen, C.C., Lee, D.D., Chang, Y.T., Wang, W.J., Liu, H.N., Cancer risk in patients with allergic rhinitis, asthma and atopic dermatitis: a nationwide cohort study in Taiwan. Int. J. Cancer 130:March (5) (2012), 1160–1167.
33. [33] El-Zein, M., Kâ, K., St-Pierre, Y., Rousseau, M.C., History of asthma or eczema and cancer risk among men: a population-based case-control study in Montreal, Quebec, Canada. Ann. Allergy. Asthma. Immunol. 104:May (5) (2010), 378–384.
34. [34] Hajdarbegovic, E., Atiq, N., van der Leest, R., Thio, B., Nijsten, T., Atopic dermatitis is not a protective factor for melanoma but asthma may be. Int. J. Clin. Oncol. 19:August (4) (2014), 708–711.
35. [35] Kölmel, K.F., Compagnone, D., [Melanoma and atopy]. Dtsch. Med. Wochenschr. 113:February (5) (1988), 169–171.
36. [36] Cheng, J., Zens, M.S., Duell, E., Perry, A.E., Chapman, M.S., Karagas, M.R., History of allergy and atopic dermatitis in relation to squamous cell and basal cell carcinoma of the skin. Cancer Epidemiol. Biomarkers Prev. 24:April (4) (2015), 749–754.
37. [37] Milán, T., Verkasalo, P.K., Kaprio, J., Koskenvuo, M., Lifestyle differences in twin pairs discordant for basal cell carcinoma of the skin. Br. J. Dermatol. 149:July (1) (2003), 115–123.
38. [38] Hajdarbegovic, E., Blom, H., Verkouteren, J.A., Hofman, A., Hollestein, L., Nijsten, T., Atopic dermatitis is not associated with actinic keratosis: cross-sectional results from the Rotterdam study. Br. J. Dermatol.(January), 2016 Epub ahead of print.
39. [39] Dyer, R.K., Weinstock, M.A., Cohen, T.S., Rizzo, A.E., Bingham, S.F., VATTC Trial Group, Predictors of basal cell carcinoma in high-risk patients in the VATTC (VA Topical Tretinoin Chemoprevention) trial. J. Invest. Dermatol. 132:November (11) (2012), 2544–2551.
40. [40] Kemp, A.S., Ponsonby, A.L., Pezic, A., Cochrane, J.A., Dwyer, T., Jones, G., The influence of sun exposure in childhood and adolescence on atopic disease at adolescence. Pediatr. Allergy Immunol. 24:August (5) (2013), 493–500.
41. [41] Silverberg, J.I., Hanifin, J., Simpson, E.L., Climatic factors are associated with childhood eczema prevalence in the United States. J. Invest. Dermatol. 133:July (7) (2013), 1752–1759.
42. [42] Dulon, M., Weichenthal, M., Blettner, M., Breitbart, M., Hetzer, M., Greinert, R., Baumgardt-Elms, C., Breitbart, E.W., Sun exposure and number of nevi in 5- to 6-year-old European children. J. Clin. Epidemiol. 55:November (11) (2002), 1075–1081.
43. [43] Wachsmuth, R.C., Turner, F., Barrett, J.H., Gaut, R., Randerson-Moor, J.A., Bishop, D.T., Bishop, J.A., The effect of sun exposure in determining nevus density in UK adolescent twins. J. Invest. Dermatol. 124:January (1) (2005), 56–62.
44. [44] Garssen, J., Vandebriel, R.J., De Gruijl, F.R., Wolvers, D.A., Van Dijk, M., Fluitman, A., Van Loveren, H.U.V.B., exposure-induced systemic modulation of Th1- and Th2-mediated immune responses. Immunology 97:July (3) (1999), 506–514.
45. [45] Thyssen, J.P., Zirwas, M.J., Elias, P.M., Potential role of reduced environmental UV exposure as a driver of the current epidemic of atopic dermatitis. J. Allergy Clin. Immunol. 136:November (5) (2015), 1163–1169.
46. [46] Thomas, N.E., Edmiston, S.N., Alexander, A., Millikan, R.C., Groben, P.A., Hao, H., Tolbert, D., Berwick, M., Busam, K., Begg, C.B., Mattingly, D., Ollila, D.W., Tse, C.K., Hummer, A., Lee-Taylor, J., Conway, K., Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol. Biomarkers Prev. 16:May (5) (2007), 991–997.
47. [47] Swope, V.B., Abdel-Malek, Z., Kassem, L.M., Nordlund, J.J., Interleukins 1 alpha and 6 and tumor necrosis factor-alpha are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J. Invest. Dermatol. 96:February (2) (1991), 180–185.
48. [48] Krasagakis, K., Garbe, C., Eberle, J., Orfanos, C.E., Tumour necrosis factors and several interleukins inhibit the growth and modulate the antigen expression of normal human melanocytes in vitro. Arch. Dermatol. Res. 287:3–4 (1995), 259–265.
49. [49] Palmer, C.N., Irvine, A.D., Terron-Kwiatkowski, A., Zhao, Y., Liao, H., Lee, S.P., Goudie, D.R., Sandilands, A., Campbell, L.E., Smith, F.J., O'Regan, G.M., Watson, R.M., Cecil, J.E., Bale, S.J., Compton, J.G., DiGiovanna, J.J., Fleckman, P., Lewis-Jones, S., Arseculeratne, G., Sergeant, A., Munro, C.S., El Houate, B., McElreavey, K., Halkjaer, L.B., Bisgaard, H., Mukhopadhyay, S., McLean, W.H., Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet. 38:April (4) (2006), 441–446.
50. [50] Elias, P.M., Schmuth, M., Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr. Opin. Allergy Clin. Immunol. 9:October (5) (2009), 437–446.
51. [51] Kaae, J., Szecsi, P.B., Meldgaard, M., Espersen, M.L., Stender, S., Johansen, J.D., Bandier, J., Thyssen, J.P., Menné, T., Nielsen, S.L., Høgdall, E., Balslev, E., Skov, L., Individuals with complete filaggrin deficiency may have an increased risk of squamous cell carcinoma. Br. J. Dermatol. 170:June (6) (2014), 1380–1381.
52. [52] Skaaby, T., Husemoen, L.L., Thyssen, J.P., Meldgaard, M., Thuesen, B.H., Pisinger, C., Jørgensen, T., Carlsen, K., Johansen, J.D., Menné, T., Szecsi, P.B., Stender, S., Linneberg, A., Filaggrin loss-of-function mutations and incident cancer: a population-based study. Br. J. Dermatol. 171:December (6) (2014), 1407–1414.
53. [53] Yeatman, J.M., Kilkenny, M., Marks, R., The prevalence of seborrhoeic keratoses in an Australian population: does exposure to sunlight play a part in their frequency?. Br. J. Dermatol. 137:September (3) (1997), 411–414.
54. [54] Aldrich, N., Gerstenblith, M., Fu, P., Tuttle, M.S., Varma, P., Gotow, E., Cooper, K.D., Mann, M., Popkin, D.L., Genetic vs environmental factors that correlate with rosacea: a cohort-based survey of twins. JAMA Dermatol. 151:November (11) (2015), 1213–1219.
55. [55] Byremo, G., Rød, G., Carlsen, K.H., Effect of climatic change in children with atopic eczema. Allergy 61:December (12) (2006), 1403–1410.
56. [56] Vähävihu, K., Ylianttila, L., Salmelin, R., Lamberg-Allardt, C., Viljakainen, H., Tuohimaa, P., Reunala, T., Snellman, E., Heliotherapy improves vitamin D balance and atopic dermatitis. Br. J. Dermatol. 158:June (6) (2008), 1323–1328.
57. [57] Patrizi, A., Savoia, F., Giacomini, F., Tabanelli, M., Gurioli, C., The effect of summer holidays and sun exposure on atopic dermatitis. G. Ital. Dermatol. Venereol. 144:August (4) (2009), 463–466.
58. [58] Carr, W.W., Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Paediatr. Drugs 15:August (4) (2013), 303–310.
59. [59] Briefing document from Angelika Manthripragada, Epidemiologist, Division of Epidemiology, Office of Surveillance and Epidemiology, FDA Center for Drug Evaluation and Research. Calcineurin inhibitor pediatric literature review, 23 Sept 2010. Available: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM255139.pdf. (accessed 11.05.16.).
60. [60] Hui, R.L., Lide, W., Chan, J., Schottinger, J., Yoshinaga, M., Millares, M., Association between exposure to topical tacrolimus or pimecrolimus and cancers. Ann. Pharmacother. 43:December (12) (2009), 1956–1963.
61. [61] Naylor, M., Elmets, C., Jaracz, E., Rico, J.M., Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. J. Dermatolog. Treat. 16:August (3) (2005), 149–153.
62. [62] Margolis, D.J., Hoffstad, O., Bilker, W., Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 214:4 (2007), 289–295.